Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Harvard Business School
Express Scripts
McKesson
AstraZeneca

Last Updated: July 4, 2020

DrugPatentWatch Database Preview

ARIKAYCE KIT Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Arikayce Kit patents expire, and what generic alternatives are available?

Arikayce Kit is a drug marketed by Insmed Inc and is included in one NDA. There are ten patents protecting this drug.

This drug has one hundred and fifty-nine patent family members in twenty-nine countries.

The generic ingredient in ARIKAYCE KIT is amikacin sulfate. There are fifteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the amikacin sulfate profile page.

US ANDA Litigation and Generic Entry Outlook for Arikayce Kit

A generic version of ARIKAYCE KIT was approved as amikacin sulfate by TEVA PHARMS USA on September 28th, 1993.

  Start Trial

Summary for ARIKAYCE KIT
International Patents:159
US Patents:10
Applicants:1
NDAs:1
Clinical Trials: 4
Formulation / Manufacturing:see details
DailyMed Link:ARIKAYCE KIT at DailyMed
Drug patent expirations by year for ARIKAYCE KIT
Recent Clinical Trials for ARIKAYCE KIT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Insmed IncorporatedPhase 2
National Institute of Allergy and Infectious Diseases (NIAID)Phase 2
Insmed IncorporatedPhase 3

See all ARIKAYCE KIT clinical trials

US Patents and Regulatory Information for ARIKAYCE KIT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Insmed Inc ARIKAYCE KIT amikacin sulfate SUSPENSION, LIPOSOMAL;INHALATION 207356-001 Sep 28, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Insmed Inc ARIKAYCE KIT amikacin sulfate SUSPENSION, LIPOSOMAL;INHALATION 207356-001 Sep 28, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Insmed Inc ARIKAYCE KIT amikacin sulfate SUSPENSION, LIPOSOMAL;INHALATION 207356-001 Sep 28, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Insmed Inc ARIKAYCE KIT amikacin sulfate SUSPENSION, LIPOSOMAL;INHALATION 207356-001 Sep 28, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Insmed Inc ARIKAYCE KIT amikacin sulfate SUSPENSION, LIPOSOMAL;INHALATION 207356-001 Sep 28, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Harvard Business School
Express Scripts
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.